Erika Krasnickas Keeton

Author

Dana-Farber Cancer Institute

Also Known As

E. Keeton, E.K. Keeton, Erika K. Keeton, Erika Keeton, Erika Krasnickas Keeton, Victor Ho-Fun Lee

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Dartmouth–Hitchcock Medical Center Riverside Methodist Hospital Florida Cancer Specialists & Research Institute

About

Erika Krasnickas Keeton is an author at Dana-Farber Cancer Institute specializing in medicine, transcriptional regulation, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	2.3K
2	Cell Biology	2	2	802
3	Natural Sciences	1	1	100
4	Biochemistry	1	1	100
5	Chemical Biology	1	1	100

Erika Krasnickas Keeton

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Genome-wide analysis of estrogen receptor binding sites Jason S. Carroll, Clifford A. Meyer, Jun S. Song, Nature Genetics Functional GenomicsHormonal ReceptorGeneticsComputational BiologyPathway Analysis	2006	1.4K
A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer Growth Qianben Wang, Wei Li, X. Shirley Liu, Molecular Cell Transcriptional RegulationSystems BiologyLineage PlasticityHormonal ReceptorHierarchical Network	2007	700
Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer Jérôme Eeckhoute, Erika Krasnickas Keeton, Mathieu Lupien, Cancer Research	2007	350
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia Erika Krasnickas Keeton, Kristen McEachern, Keith Dillman, Blood	2013	240
Coactivator AIB1 links estrogen receptor transcriptional activity and stability Wenlin Shao, Erika Krasnickas Keeton, Donald P. McDonnell, Proceedings of the National Academy of Sciences	2004	131
Cell Cycle Progression Stimulated by Tamoxifen-Bound Estrogen Receptor-α and Promoter-Specific Effects in Breast Cancer Cells Deficient in N-CoR and SMRT Erika Krasnickas Keeton, Myles Brown Molecular Endocrinology Breast OncologyCancer BiologyMammary Gland DevelopmentTumor BiologyTranscriptional Regulation	2005	102
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases Les A. Dakin, M. Block, Huawei Chen, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryNovel Benzylidene-1,3-thiazolidine-2,4-dionesBiochemistryNatural SciencesMedicine	2012	100
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Gynecologic Oncology	2022	95
PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer Austin N. Kirschner, Jie Wang, Riet van der Meer, JNCI Journal of the National Cancer Institute	2014	86
Glucocorticoid Receptor Domain Requirements for Chromatin Remodeling and Transcriptional Activation of the Mouse Mammary Tumor Virus Promoter in Different Nucleoprotein Contexts Erika Krasnickas Keeton, Terace M. Fletcher, Christopher T. Baumann, Journal of Biological Chemistry	2002	26

Page 1